Effect of Garenoxacin to fever and pro-inflamatory cytokine with bronchoscopy

Not Applicable

• Conditions: fever and increase of pro-inflamatory cytokine with bronchoalveolar lavage

• Registration Number: JPRN-UMIN000004387
• Lead Sponsor: Keio University Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2010-10-14
• Study Completion: 2019-03-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Not provided

Exclusion Criteria

(1) patient who has history of hypersensitivity reaction or adverse event to quinolones (2) patients who can't be performed bronchoscopy because of respirotry disorder (3) patient who has disability of oral administration (4) patient who has history of convulsion or epilepsy or who has regular administration of anti- epileptic medicine (5) patients who has autoimmune disease or immuno-disorders (6) patients who has administration of systemic corticosteroid (7) patients who are administerd antibiotics within 2 weeks (8) pregnanct or possibility of pregnant or breast feeding (9) patients not suitable to administration of garenoxacin considered by attending physician (10) patients who has possibility of negative impact to diagnosis by administration of garenoxacin

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
pro-inflamatory cytokine(IL-1, IL-2, IL-6, IL-10), procalcitonin

Secondary Outcome Measures

Name	Time	Method
fever, leukocytosis, CRP